Ash Stevens Inc. CEO to Chair Session on Cancer Drug Development at American Association for Cancer Research Annual Meeting
Detroit – April 8, 2009 – Ash Stevens Inc.™ (ASI) President and CEO Dr. Stephen Munk will chair an educational session for the Chemistry in Cancer Research Working Group (CICR) at the American Association for Cancer Research (AACR) annual meeting on Saturday, April 18, 2009 at the Colorado Convention Center in Denver, Colorado.
Dr. Munk's session will highlight the unique developmental challenges of safely manufacturing highly potent active pharmaceutical ingredients (APIs) used in cancer drugs. Speakers from a broad range of research institutions involved with early stage compounds and approved drugs will participate including Southern Research Institute, Medivation, Inc., and Millennium Pharmaceuticals, Inc.. The title of the session is "From Chemistry to the Clinic: Pathways for Drug Discovery and Development Part 4: Chemical Development - Translating a Potent Agent into a Registered Product".
About Ash Stevens, Inc.
Headquartered in Detroit, Ash Stevens, Inc. (ASI) was founded in 1962 to service the
chemical research needs of the Federal Government. ASI has extensive experience in
the development and scale-up of commercial cancer APIs and shares a longstanding
and successful relationship with the National Cancer Institute. ASI has a total of 11 FDA
approved drug substances in its portfolio. The company has more than 60 employees
and holds a variety of patents covering topics including medicinal agents and
manufacturing processes. For more information, visit www.ashstevens.com.
To download a PDF version please, click here.